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Abstract
Background
Obesity is positively associated with colorectal cancer. Recently, body size subtypes cate-
gorised by the prevalence of hyperinsulinaemia have been defined, and metabolically
healthy overweight/obese individuals (without hyperinsulinaemia) have been suggested to
be at lower risk of cardiovascular disease than their metabolically unhealthy (hyperinsuli-
naemic) overweight/obese counterparts. Whether similarly variable relationships exist for
metabolically defined body size phenotypes and colorectal cancer risk is unknown.
Methods and Findings
The association of metabolically defined body size phenotypes with colorectal cancer was
investigated in a case–control study nested within the European Prospective Investigation
into Cancer and Nutrition (EPIC) study. Metabolic health/body size phenotypes were defined
according to hyperinsulinaemia status using serum concentrations of C-peptide, a marker of
insulin secretion. A total of 737 incident colorectal cancer cases and 737 matched controls
were divided into tertiles based on the distribution of C-peptide concentration amongst the
control population, and participants were classified as metabolically healthy if below the first
tertile of C-peptide and metabolically unhealthy if above the first tertile. These metabolic
health definitions were then combined with body mass index (BMI) measurements to create
four metabolic health/body size phenotype categories: (1) metabolically healthy/normal
weight (BMI < 25 kg/m2), (2) metabolically healthy/overweight (BMI 25 kg/m2), (3) metabol-
ically unhealthy/normal weight (BMI < 25 kg/m2), and (4) metabolically unhealthy/overweight
(BMI 25 kg/m2). Additionally, in separate models, waist circumference measurements
(using the International Diabetes Federation cut-points [80 cm for women and94 cm for
men]) were used (instead of BMI) to create the four metabolic health/body size phenotype
categories. Statistical tests used in the analysis were all two-sided, and a p-value of <0.05
was considered statistically significant. In multivariable-adjusted conditional logistic regres-
sion models with BMI used to define adiposity, compared with metabolically healthy/normal
weight individuals, we observed a higher colorectal cancer risk among metabolically
unhealthy/normal weight (odds ratio [OR] = 1.59, 95% CI 1.10–2.28) and metabolically
unhealthy/overweight (OR = 1.40, 95%CI 1.01–1.94) participants, but not among metaboli-
cally healthy/overweight individuals (OR = 0.96, 95%CI 0.65–1.42). Among the overweight
individuals, lower colorectal cancer risk was observed for metabolically healthy/overweight
individuals compared with metabolically unhealthy/overweight individuals (OR = 0.69, 95%
CI 0.49–0.96). These associations were generally consistent when waist circumference was
used as the measure of adiposity. To our knowledge, there is no universally accepted clinical
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definition for using C-peptide level as an indication of hyperinsulinaemia. Therefore, a possi-
ble limitation of our analysis was that the classification of individuals as being hyperinsulinae-
mic—based on their C-peptide level—was arbitrary. However, when we used quartiles or the
median of C-peptide, instead of tertiles, as the cut-point of hyperinsulinaemia, a similar pat-
tern of associations was observed.
Conclusions
These results support the idea that individuals with the metabolically healthy/overweight
phenotype (with normal insulin levels) are at lower colorectal cancer risk than those with
hyperinsulinaemia. The combination of anthropometric measures with metabolic parame-
ters, such as C-peptide, may be useful for defining strata of the population at greater risk of
colorectal cancer.
Introduction
Obesity has been consistently associated with increased risks of certain chronic diseases, such
as cardiovascular disease (CVD), type 2 diabetes (T2D), and cancer [1–4]. High body mass
index (BMI) and several other measures of adiposity have been consistently and strongly asso-
ciated with colorectal cancer. In the European Prospective Investigation into Cancer and Nutri-
tion (EPIC), men and women in the highest quintile of waist circumference had a 40% and
50% higher risk, respectively, of developing colon cancer compared to those in the lowest quin-
tile [5]. A meta-analysis of 30 cohort studies reported elevated risks (relative risks) for those
categorised as overweight (25–29.9 kg/m2) and obese (30 kg/m2) of 1.13 (95% CI 1.06–1.19)
and 1.31 (95% CI 1.19–1.45), respectively [2].
Hyperinsulinaemia and insulin resistance are commonly present in obese individuals and
have been hypothesised to play a role in the aetiology of colorectal cancer [6]. For instance,
higher circulating insulin levels have been previously associated with greater colorectal cancer
risk [7,8]. Other studies have assessed insulin resistance by measuring the homeostatic model
assessment index of insulin resistance (HOMAIR) or levels of C-peptide, which has a longer
half-life than insulin and is considered a valid biomarker of pancreatic insulin secretion [9]. C-
peptide levels have also generally been positively associated with colorectal cancer risk [10–12].
However, for CVD, T2D, and breast cancer, accumulating evidence has identified a sub-
group of metabolically healthy overweight/obese individuals without hyperinsulinaemia who
are seemingly at lower risk than their hyperinsulinaemic, metabolically unhealthy/overweight
counterparts [13–15]. Similarly, normal-weight individuals have been subdivided into an “at
risk” phenotype based on the prevalence of hyperinsulinaemia; individuals with this phenotype
have been shown to exhibit elevated CVD, T2D, and breast cancer risks compared to their “low
risk” normal-weight equivalents without hyperinsulinaemia [13–16].
To our knowledge, no prospective studies have investigated the association of metabolically
defined body size phenotypes with colorectal cancer risk. The identification of sub-types of
body size that are associated with colorectal cancer may be useful for risk stratification and fur-
ther understanding of the pathophysiological mechanisms underlying the obesity–colorectal
cancer relationship. Therefore, in this nested case–control analysis within the EPIC prospective
cohort, we classified individuals into metabolically defined body size phenotype groups based
on the presence or absence of hyperinsulinaemia (based on C-peptide level) combined with
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anthropometric measurements. The associations of these metabolically defined body size phe-
notypes with incident colorectal cancer were then assessed.
Methods
EPIC Study Population and Collection of Blood Samples
All study participants provided written informed consent. Ethical approval for the EPIC study
was obtained from the review boards of the International Agency for Research on Cancer and
local participating centres: National Committee on Health Research Ethics (Denmark); Comité
de Protection des Personnes (France); Ethics Committee of the Heidelberg University Medical
School (Germany); Ethikkommission der Landesärztekammer Brandenburg Cottbus (Ger-
many); University of Athens Medical School (Greece) Comitato Etico Indipendente, Fonda-
zione IRCCS Istituto Nazionale dei Tumori (Italy); Human Genetics Foundation Torino Ethics
Committee (Italy); Medical Ethical Committee (METC) of the University Medical Center
Utrecht (the Netherlands); Regional Ethical Committee for Northern Norway and the Norwe-
gian Data Inspectorate (Norway); Comité de Ética de Investigación Clínica (Spain); Ethics Com-
mittee of Lund University (Sweden); Umea Regional Ethical Review Board (Sweden); Norwich
District Ethics Committee (UK); Scotland A Research Ethics Committee (UK); and the Imperial
College Research Ethics Committee (UK). EPIC is an ongoing multicentre prospective cohort
study designed to investigate the associations between diet, lifestyle, and genetic and environ-
mental factors and various types of cancer. A detailed description of the methods of the EPIC
study has previously been published [17,18]. In summary, 521,448 participants (~70% women)
mostly aged 35 y or above were recruited between 1992 and 2000. Participants were recruited
from 23 study centres in ten European countries. The present study includes participants from
Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, and the United Kingdom.
Blood samples were collected at baseline according to standardised procedures [17,18] and
stored at the International Agency for Research on Cancer (−196°C, liquid nitrogen) for all
countries except Denmark (−150°C, nitrogen vapour).
Follow-Up for Cancer Incidence and Vital Status
Incident cancer cases were identified using population cancer registries in Denmark, Italy, the
Netherlands, Spain, and the United Kingdom. In France, Germany, and Greece, cancer cases
were identified during follow-up from a combination of sources including health insurance
records, cancer and pathology registries, and active follow-up directly through study partici-
pants or their next of kin. The end of follow-up for the current study was defined as the latest
date of complete follow-up (of whole cohort) for both cancer incidence and vital status; this
ranged from December 1999 to June 2003 for centres using registry data and from June 2000 to
December 2002 for centres that used active follow-up procedures. Colorectal cancer cases were
defined using the tenth revision of the International Classification of Diseases (ICD-10) and
the second revision of the International Classification of Diseases for Oncology (ICDO-2).
Cancer of the colon included cancers within the caecum, appendix, ascending colon, hepatic
flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, overlapping sites of
colon, and unspecified sites within the colon (C18.0–18.9). Cancer of the rectum included can-
cer occurring at the rectosigmoid junction (C19) and rectum (C20).
Selection of Case and Control Participants
The current analysis uses data from a nested case–control study design in which serum C-pep-
tide level was measured in 1,078 incident colorectal cancer cases and 1,078 matched controls
Metabolically Defined Body Size Phenotypes and Colorectal Cancer Risk
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from eight EPIC countries (excluding Norway and Sweden) [11]. Participants from Norway
were not selected because the time period between blood collection and the laboratory analyses
was too short for a sufficient number of colorectal cancer cases to accrue. Cases from Sweden
were not included because an independent study of insulin and colorectal cancer risk within
that population was ongoing when the laboratory analyses were undertaken. Controls were
selected from the full cohort of individuals who were alive and free of cancer (except non-mela-
noma skin cancer) at the time of diagnosis of the cases, using incidence density sampling and
with controls matched to cases by age (±6 mo at recruitment), sex, study centre, follow-up time
since blood collection, time of day at blood collection (±4 h), fasting status, menopausal status,
and phase of menstrual cycle at blood collection. Exclusion criteria for the current analysis
included the following: individuals with diabetes (self-reported at baseline) or those with
unknown diabetic status, individuals without information on fasting status when blood was
collected, and women who reported using menopausal hormone therapy or oral contraceptives
at the time of blood collection, due to the effect of exogenous hormone use on C-peptide levels,
which may render the observed associations in hormone users uninterpretable [7]. After these
exclusions, a total of 737 incident colorectal cancer cases and 737 matched controls with avail-
able baseline information were included in the analysis.
Assessment of Anthropometric, Lifestyle, and Dietary Exposures
With participants not wearing shoes, weight was measured to the nearest 0.1 kg and height was
measured—dependent on the study centre—to the nearest 0.1, 0.5, or 1.0 cm. BMI was calcu-
lated as weight in kilograms divided by height in metres squared (kg/m2). Waist circumference
was measured either at the narrowest torso circumference or at the midpoint between the
lower ribs and iliac crest. Lifestyle questionnaires were used to obtain information on educa-
tion, smoking status, alcohol consumption, and physical activity level. Dietary information
(dietary intake of total energy, red and processed meats, and fibre, calcium, and fish) was col-
lected at baseline using validated country/centre-specific dietary questionnaires [17,18].
Laboratory Measurements
C-peptide was assayed in serum samples of all participants (radioimmunoassay; Diagnostic
System Laboratories) as previously described [11]. The mean intra-batch and inter-batch coef-
ficients of variation were 4.6% and 7.5%, respectively, for C-peptide (at a concentration of 5
ng/ml) [11]. Levels of previously measured glycated haemoglobin (HbA1c) were also available
for the majority of participants [19].
Metabolically Defined Body Size Phenotype Definitions
Participants were divided into tertiles based on the distribution of C-peptide concentration
amongst the control population (tertile cut-points: 2.96 ng/ml and 4.74 ng/ml), and were classi-
fied as metabolically healthy if below the first tertile of C-peptide and metabolically unhealthy
if above the first tertile. These metabolic health definitions were then combined with BMI or
waist circumference measurements to create four metabolic health/body size phenotype cate-
gories: (1) metabolically healthy/normal weight (BMI< 25 kg/m2 or waist circumference < 80
cm for women and< 94 cm for men), (2) metabolically healthy/overweight (BMI 25 kg/m2
or waist circumference  80 cm for women and 94 cm for men), (3) metabolically
unhealthy/normal weight (BMI< 25 kg/m2 or waist circumference< 80 cm for women
and< 94 cm for men), and (4) metabolically unhealthy/overweight (BMI 25 kg/m2 or waist
circumference 80 cm for women and 94 cm for men). The International Diabetes
Metabolically Defined Body Size Phenotypes and Colorectal Cancer Risk
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Federation (IDF) waist circumference cut-points were used [20]; these are ethnic-specific cut-
points for European populations.
Statistical Analysis
Differences between cases and controls were assessed using the Wilcoxon two-sample test or
two-sample t-test for continuous variables and the χ2 test for categorical variables. Conditional
logistic regression, stratified by case–control set, was used to compute odds ratios (ORs) and
95% confidence intervals for the associations between metabolic-health-defined body size phe-
notypes and colorectal cancer, colon cancer, and rectal cancer. The basic model (model 1) was
conditioned on including the matching criteria only, while the multivariable models (models 2
and 3) included the matching criteria plus additional adjustment for a set of a priori defined
colorectal cancer risk factors that included smoking status, physical activity, education level,
alcohol consumption, height, and dietary intakes of total energy, red and processed meats, and
fibre. Further adjustment for dietary intakes of calcium and fish resulted in virtually unchanged
risk estimates, so these two variables were excluded from the multivariable models. Models
were additionally stratified by sex and formally tested for heterogeneity using χ2 tests. Hetero-
geneity between colon and rectal cancer was tested using χ2 tests. To assess whether preclinical
disease may have influenced the results, cases diagnosed within the first 2 y of follow-up were
excluded and all analyses were redone. In sensitivity analyses, all models were rerun (1) with a
BMI cut-point of 30 kg/m2 (rather than 25 kg/m2) for metabolic health/body size phenotype
definitions and (2) with participants who had HbA1c measurements> 6.5% (the recom-
mended cut-point for diagnosing diabetes) excluded. Tests of interaction (multiplicative)
between the dichotomous body size (BMI or waist circumference) and C-peptide variables
used to define the metabolic health/body size phenotypes were assessed in separate models.
The statistical significance of these interaction terms was assessed by conducting likelihood
ratio tests on models with and without these cross-product terms. Statistical tests used in the
analysis were all two-sided, and a p-value of<0.05 was considered statistically significant.
Analyses were conducted using Stata v11.0.
Results
Colorectal cancer cases had greater waist circumference measurements than controls (Table 1).
A higher proportion of the controls were never smokers and physically active compared to the
case participants. Control participants reported lower consumption of red and processed meats
and had lower levels of serum C-peptide than cases. The median follow-up time was shorter
for colon cancer cases (3.7 y) than for rectal cancer cases (3.9 y). Compared to the metabolically
healthy/normal weight group, a greater proportion of metabolically unhealthy/normal weight
participants were physically inactive and a lower proportion never smoked (Table 2). Com-
pared to the metabolically unhealthy/overweight group, individuals in the metabolically
healthy/overweight group were less likely to be current smokers and to be physically inactive,
and they consumed less red and processed meats.
Metabolically Healthy/Overweight
Categorisation based on body mass index. Individuals with the metabolically healthy/
overweight phenotype were not at elevated risk of colorectal cancer compared to metabolically
healthy/normal weight individuals (OR = 0.96, 95% CI 0.65–1.42) (Table 3). In a sensitivity
analysis, a similar null colorectal cancer relationship was observed when the BMI cut-point of
30 kg/m2 was used (rather than 25 kg/m2) (OR = 1.09, 95% CI 0.51–2.35). Individuals classified
as metabolically healthy/overweight were at lower colorectal cancer risk than their
Metabolically Defined Body Size Phenotypes and Colorectal Cancer Risk
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Table 1. Baseline characteristics of cases and controls.
Baseline Characteristic Cases Controls p-Value*
Cancer type, n (percent)
Colorectal cancer 737 (100.0%) 737 (100.0%)
Colon cancer 444 (60.2%) 444 (60.2%)
Rectal cancer 293 (39.8%) 293 (39.8%)
Sex, n (percent)
Men 395 (53.6%) 395 (53.6%)
Women 342 (46.4%) 342 (46.4%)
Age at blood collection (years)§ 57.6 (6.4) 57.6 (6.4) 0.96
Years of follow-up§ 3.7 (2.1) —
Anthropometrics§
BMI (kg/m2) 26.9 (4.3) 26.6 (3.8) 0.16
Waist circumference (cm) 91.2 (12.8) 89.8 (12.4) 0.03
Smoking status† 0.56
Never 279 (37.9%) 306 (41.4%)
Former 246 (33.4%) 229 (30.9%)
Current 209 (28.4%) 202 (27.3%)
Physical activity† 0.06
Inactive 148 (20.1%) 121 (16.3%)
Moderately inactive 218 (29.6%) 195 (26.3%)
Moderately active 296 (40.2%) 332 (44.8%)
Active 72 (9.8%) 85 (11.5%)
Education level† 0.77
None/primary school completed 297 (40.3%) 315 (42.5%)
Technical/professional school 177 (24.0%) 183 (24.7%)
Secondary school 105 (14.3%) 91 (12.3%)
Longer education (including university degree) 146 (19.8%) 139 (18.8%)
Fasting status at blood collection† 1.00
Not fasting 374 (50.8%) 374 (50.8%)
In between 155 (21.0%) 155 (21.0%)
Fasting 208 (28.2%) 208 (28.2%)
Dietary intakes
Alcohol consumption (g/d)‡ 11.8 (2.3–29.7) 12.0 (2.7–26.4) 0.27
Red and processed meats (g/d)‡ 88.3 (58.2–122.7) 83.9 (52.2–121.8) 0.10
Fibre (g/d)§ 23.3 (7.8) 23.9 (8.2) 0.13
Total energy (kcal/d)‡ 2,150 (1,761–2,559) 2,131 (1,734–2,563) 0.44
C-peptide (ng/ml)‡ 3.9 (2.8–5.9) 3.7 (2.6–5.4) 0.01
Metabolic health/BMI deﬁnitiona 0.01
Metabolically healthy/normal weight 101 (13.7%) 131 (17.8%)
Metabolically healthy/overweight 93 (12.6%) 121 (16.4%)
Metabolically unhealthy/normal weight 158 (21.4%) 133 (18.0%)
Metabolically unhealthy/overweight 385 (52.2%) 352 (47.8%)
Metabolic health/waist circumference deﬁnitionb 0.004
Metabolically healthy/normal weight 113 (15.5%) 153 (20.9%)
Metabolically healthy/overweight 80 (10.9%) 97 (13.3%)
Metabolically unhealthy/normal weight 160 (21.9%) 168 (23.0%)
(Continued)
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metabolically unhealthy/overweight counterparts (OR = 0.69, 95% CI 0.49–0.96) (Table 3). No
statistically significant heterogeneity was observed when colon cancer and rectal cancer were
compared (p for heterogeneity = 0.47), and when men and women were analysed separately (p
for heterogeneity = 0.17).
Categorisation based on waist circumference. When waist circumference cut-points
were used to categorise participants, metabolically healthy/overweight participants were, once
more, at lower risk of colorectal cancer risk (OR = 0.67, 95% CI 0.47–0.97) than the metaboli-
cally unhealthy/overweight group, and not at higher risk than metabolically healthy/normal
weight individuals (Table 3). There was no statistically significant difference in the associations
when colon cancer and rectal cancer were compared (p for heterogeneity = 0.25), and when
men and women were analysed separately (p for heterogeneity = 0.19).
Metabolically Unhealthy/Normal Weight
Categorisation based on body mass index. Higher colorectal cancer risk (OR = 1.59,
95% CI 1.10–2.28) was observed amongst metabolically unhealthy/normal weight partici-
pants than among their metabolically healthy/normal weight counterparts (Table 3). This
positive association persisted following additional adjustment for waist circumference
(OR = 1.52, 95% CI 1.05–2.20). There was no statistically significant difference in the associa-
tions for rectal cancer compared to colon cancer (p for heterogeneity = 0.50) or by sex (p for
heterogeneity = 0.26).
Categorisation based on waist circumference. Non-significantly higher colorectal can-
cer risk was observed for metabolically unhealthy/normal weight participants compared to
metabolically healthy/normal weight participants when IDF waist circumference cut-points
(80 cm in women and 94 cm in men) were used as the marker of adiposity (Table 3). No
statistically significant heterogeneity was observed when men and women were analysed sep-
arately (p for heterogeneity = 0.22). When compared versus the metabolically healthy/normal
weight group, a statistically significant positive association was observed for metabolically
Table 1. (Continued)
Baseline Characteristic Cases Controls p-Value*
Metabolically unhealthy/overweight 378 (51.7%) 313 (42.8%)
For the metabolic health/BMI models, the category deﬁnitions are as follows: metabolically healthy/normal weight is individuals with normal BMI (<25 kg/
m2) and below tertile 1 of C-peptide; metabolically healthy/overweight is individuals with overweight/obese BMI (25 kg/m2) plus below tertile 1 of C-
peptide; metabolically unhealthy/normal weight is individuals with normal BMI (<25 kg/m2) plus above tertile 1 of C-peptide; metabolically unhealthy/
overweight is individuals with overweight/obese BMI (25 kg/m2) plus above tertile 1 of C-peptide. The C-peptide tertile cut-points were 2.96 ng/ml and
4.74 ng/ml. For the metabolic health/IDF waist circumference models, the category deﬁnitions are as follows: metabolically healthy/normal weight is
individuals with waist circumference below IDF cut-point (<80 cm in women; <94 cm in men) plus below tertile 1 of C-peptide; metabolically healthy/
overweight is individuals with waist circumference above IDF cut-point (80 cm in women; 94 cm in men) plus below tertile 1 of C-peptide; metabolically
unhealthy/normal weight is individuals with waist circumference below IDF cut-point (<80 cm in women; <94 cm in men) plus above tertile 1 of C-peptide;
metabolically unhealthy/overweight is individuals with waist circumference above IDF cut-point (80 cm in women; 94 cm in men) plus above tertile 1 of
C-peptide.
*Calculated using Wilcoxon two-sample test or two-sample t-test for continuous variables and χ2 test for categorical variables.
§Values are mean (standard deviation).
†Values are n (percent) with participants with any missing/unknown values for baseline characteristics excluded.
‡Values are median (interquartile range).
aValues are n (percent) based on 737 cases and 737 control participants.
bValues are n (percent) based on 731 cases and 731 control participants.
doi:10.1371/journal.pmed.1001988.t001
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unhealthy/normal weight participants for rectal cancer (OR = 1.76, 95% CI 1.01–3.05) but
not for colon cancer (OR = 1.18, 95% CI 0.74–1.88), although this difference in association
for rectal versus colon cancer was non-significant (p for heterogeneity = 0.33).
Metabolically Unhealthy/Overweight
Categorisation based on body mass index. Among the metabolically unhealthy/over-
weight group, higher colorectal cancer risk was observed compared with the metabolically
healthy/normal weight individuals (OR = 1.40, 95% CI 1.01–1.94) (Table 3). No statistically
significant heterogeneity in the relationship was observed for colon cancer and rectal cancer (p
for heterogeneity = 0.47) or when men and women were analysed separately (p for heterogene-
ity = 0.32). A greater increased colon cancer risk was observed amongst the metabolically
unhealthy/overweight group (OR = 1.75, 95% CI 1.11–2.77) than for overweight per se (i.e.,
when BMI was entered into the model as a dichotomous variable without consideration of
hyperinsulinaemia; BMI 25 versus< 25 kg/m2, OR = 1.14, 95% CI 0.82–1.59).
Categorisation based on waist circumference. Higher colorectal cancer risk was observed
among metabolically unhealthy/overweight individuals than among their metabolically
healthy/normal weight counterparts (OR = 1.66, 95% CI 1.20–2.28) (Table 3). This positive
relationship was statistically significant for colon cancer (OR = 2.12, 95% CI 1.38–3.27) but not
for rectal cancer (OR = 1.36, 95% CI 0.82–2.26), although this difference in association for rec-
tal versus colon cancer was non-significant (p for heterogeneity = 0.21). The positive colon can-
cer association for the metabolically unhealthy/overweight group was stronger than when
waist circumference was entered into the model as a dichotomous variable without consider-
ation of C-peptide level (80 cm women and94 cm men versus<80 cm women and<94
cm men, OR = 1.58, 95% CI 1.14–2.19).
Sensitivity Analyses
Exclusion of participants with HbA1c values> 6.5% (indicative of possible sub-clinical diabe-
tes) did not lead to any appreciable change in the study results for any group versus metaboli-
cally healthy/normal weight based on BMI (metabolically healthy/overweight, OR = 0.98, 95%
CI 0.65–1.48; metabolically unhealthy/normal weight, OR = 1.68, 95% CI 1.14–2.47; metaboli-
cally unhealthy/overweight OR = 1.35, 95% CI: 0.95–1.92) or waist circumference (metaboli-
cally healthy/overweight, OR = 1.08, 95% CI 0.70–1.68; metabolically unhealthy/normal
weight, OR = 1.32, 95% CI 0.91–1.91; metabolically unhealthy/overweight, OR = 1.64, 95% CI
1.16–2.32). A similar pattern of results was observed when the first quartile or median C-pep-
tide value, rather than the first tertile, was used to define metabolic health (hyperinsulinaemia)
for the body size phenotypes (S1 Table). A similar pattern of results were observed when cases
diagnosed within the first 2 y of follow-up were excluded (S2 Table). The p-interaction values
between the dichotomous BMI and C-peptide variables used to define the metabolic health/
body size phenotypes were as follows: colorectal cancer, p = 0.72; colon cancer, p = 0.35; and
rectal cancer, p = 0.09. The p-interaction values between the dichotomous waist circumference
and C-peptide variables used to define the metabolic health/body size phenotypes were as fol-
lows: colorectal cancer, p = 0.69; colon cancer, p = 0.03; and rectal cancer, p = 0.05.
Discussion
The results of this prospective investigation indicate that normal-weight individuals with
hyperinsulinaemia (the metabolically unhealthy/normal weight phenotype) are at higher colo-
rectal cancer risk than those of normal-weight without hyperinsulinaemia. Our results also
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support the notion that metabolically healthy/overweight individuals, with normal insulin lev-
els, are at reduced risk of colorectal cancer compared to their hyperinsulinaemic counterparts.
To our knowledge, this is the first investigation of hyperinsulinaemia-defined body size phe-
notypes and colorectal cancer risk in a prospective cohort setting. A number of studies have
previously investigated the relationships of body size phenotypes with CVD, T2D, and breast
cancer risks, and have reported elevated risks among metabolically unhealthy/normal weight
individuals compared to their metabolically healthy/normal weight counterparts [13–16]. We
observed a similar positive association for the metabolically unhealthy/normal weight pheno-
type when BMI and waist circumference were used as the anthropometric measure, and a sta-
tistically significant relationship was present only for rectal cancer and not for colon cancer.
This result suggests that hyperinsulinaemia, independent of body size, may be a more relevant
aetiological factor than adiposity per se; this is consistent with mitogenic and anti-apoptotic
effects of insulin on the colon mucosa. Hypothesised causes of hyperinsulinaemia in normal-
weight individuals, beyond an accumulation of visceral fat, may include low physical activity
levels [21], low fibre intake [22], and changes in the actions of pro-inflammatory and anti-
inflammatory cytokines [22,23].
In the metabolically healthy/overweight group, we observed no increased risk for colorectal
cancer. This result is inconsistent with a recent Korean cross-sectional analysis that reported a
59% greater (OR 1.59, 95% CI 1.04–2.43) prevalence of high-risk colorectal adenoma for meta-
bolically healthy/overweight individuals than for metabolically healthy/normal weight individ-
uals [24]. In this previous analysis, the definition of metabolically unhealthy incorporated
insulin resistance and metabolic syndrome criteria, such as blood pressure and abnormal levels
of blood glucose and blood lipids. Within EPIC, when metabolic syndrome components and
cut-points were analysed within the same multivariable model, only abnormal levels of blood
glucose (as assessed by HbA1c measurements) were associated with colon cancer and rectal
cancer [25]. These findings may reflect other potential mechanisms related to high abdominal
fat accumulation being important for colorectal cancer risk, independent of hyperinsulinaemia.
For example, visceral adipose tissue generates hormones and cytokines with inflammatory,
metabolic, and direct carcinogenic potential, which may directly or indirectly increase colorec-
tal cancer risk [26]. Therefore, potential pathways to explain this association include chronic
low-grade inflammation and alterations in adipokine concentrations [26]. Future studies may
shed more light on underlying pathophysiological mechanisms.
The increased colorectal cancer risk observed among the metabolically unhealthy/over-
weight group was present when both BMI and waist circumference measurements were used as
markers of adiposity. Previous studies have shown a strong association between waist circum-
ference and colon cancer [1,2,5]. In our analysis, a 58% greater risk of colon cancer was
observed among participants above the IDF waist circumference cut-point (80 cm in women
and 94 cm in men) compared to those below the cut-point. Interestingly, when individuals
were subdivided into hyperinsulinaemia/body size phenotype groups, a higher risk estimate for
the metabolically unhealthy/overweight group was observed (a 112% higher colon cancer risk).
Overall, our results suggest that simply identifying those at greater risk of developing colorectal
cancer by high BMI or waist circumference measurement would exclude normal-weight indi-
viduals with hyperinsulinaemia and underestimate the risk amongst overweight individuals
with hyperinsulinaemia. Earlier identification of such individuals could lead to appropriate tar-
geted interventions being introduced, which could prevent the onset of clinical disease.
A strength of our study is its prospective design, i.e., that pre-diagnostic measurements of
C-peptide were used. Although the follow-up period was relatively short, a similar pattern of
results was observed when cases with less than 2 y of follow-up were excluded. Our use of C-
peptide level as a marker of insulin resistance, rather than the HOMAIR (using insulin and
Metabolically Defined Body Size Phenotypes and Colorectal Cancer Risk
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glucose measures), was justified as C-peptide is a validated marker of hyperinsulinaemia [9]
and has been previously associated with colorectal cancer risk [11,12]. A limitation is that the
classification of individuals as hyperinsulinaemic—based on their C-peptide level—was arbi-
trary. However, when we used the first quartile or median of C-peptide, instead of the first ter-
tile, as the cut-point of hyperinsulinaemia, a similar pattern of associations was observed. A
possible limitation was that our study lacked statistical power for some of the sub-group analy-
ses, e.g., for the analysis of metabolically healthy/overweight participants compared with the
metabolically healthy/normal weight group; however, we estimated that we had 70% power (α
= 0.05, two-sided test) to observe a similar relationship to what was found for the metabolically
unhealthy/overweight group (OR 2.1). An additional potential limitation was that data on use
of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) that have been linked
with reduced risk of colorectal cancer were not available for the majority of study participants
and could therefore not be considered as a possible covariate in our multivariable models.
However, we feel it is unlikely that aspirin or NSAID use would significantly confound the
observed associations between hyperinsulinaemia-defined body size phenotypes and colorectal
cancer, since previously reported associations of adiposity, C-peptide, and other hyperinsuli-
naemia parameters with colorectal cancer risk were unaffected by adjustment for aspirin or
NSAID use [7,12,27,28].
Our results indicate that sub-classifying populations by hyperinsulinaemia and adiposity
measurements could identify differential colorectal cancer risk relationships for the defined
metabolic health/body size phenotypes. Our results were supportive of individuals with the
metabolically healthy/overweight phenotype being at lower colorectal cancer risk than those
with hyperinsulinaemia and suggest that the assessment of insulin level in conjunction with
adiposity measures may be of greater value in the assessment of colorectal cancer risk than adi-
posity per se.
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Editors' Summary
Background
Colorectal cancer is the third most common cancer worldwide and is a leading cause of
cancer-related death, killing around 700,000 people every year. It develops when cells in
the colon (the final part of the digestive system, which is also known as the large intestine
or large bowel) or the rectum (the lower end of the colon) acquire genetic changes that
allow them to divide uncontrollably to form a tumor and to move around the body (metas-
tasize). Symptoms of colorectal cancer include blood in the stool, a change in bowel habits,
and unexplained weight loss. Treatments for colorectal cancer include surgery, chemother-
apy, and radiation. As with other types of cancer, these treatments are more likely to be
successful if started when the tumor is very small. Consequently, many countries run
screening programs that use colonoscopy, the fecal occult blood test, and other tests to
detect the earliest signs of colorectal cancer in apparently healthy people.
WhyWas This Study Done?
Being obese—having too much body fat—is associated with an increased colorectal cancer
risk (other risk factors include age, having a family history of colorectal cancer, and eating
a high-fat, low-fiber diet). Obesity is also associated with several other chronic diseases,
and recent evidence suggests that some obese individuals have a higher risk of developing
these diseases than others. For example, overweight/obese individuals who have hyperin-
sulinemia (abnormally high blood levels of insulin; “metabolically unhealthy”) seem to
have a higher risk of cardiovascular disease than their non-hyperinsulinemic (“metaboli-
cally healthy”) overweight counterparts. If certain combinations of metabolic health status
and body size (“metabolically defined body size phenotypes”) are also associated with
colorectal cancer, measurement of insulin levels in conjunction with body fat (adiposity)
measurements such as body mass index (BMI; an indicator of body fat calculated by divid-
ing a person’s weight in kilograms by their height in meters squared) might improve colo-
rectal cancer risk assessment. In this nested case–control study, the researchers assess the
associations between metabolically defined body size phenotypes and colorectal cancer
risk. A nested case–control study identifies everyone in a group (here, participants in the
European Prospective Investigation into Cancer and Nutrition [EPIC] study) who has a
specific condition, identifies matched individuals in the same group without the condition,
and asks whether these controls and the cases differ in terms of a specific characteristic or
outcome.
What Did the Researchers Do and Find?
The researchers matched 737 participants in the EPIC study who developed colorectal
cancer after study enrollment with 737 controls and used serum concentrations of C-pep-
tide, a marker of insulin secretion, and BMI measurements to classify each individual as
metabolically healthy/normal weight, metabolically healthy/overweight, metabolically
unhealthy/normal weight, or metabolically unhealthy/overweight. Specifically, the
researchers categorized people as metabolically unhealthy if they had a C-peptide level
above an arbitrarily chosen cut-off value based on the distribution of C-peptide levels in
the control participants and as overweight if they had a BMI of25 kg/m2 (the standard
definition of overweight). Compared to metabolically healthy normal weight individuals,
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metabolically unhealthy normal weight and overweight individuals had an increased colo-
rectal cancer risk; metabolically healthy overweight individuals had a similar colorectal
cancer risk to metabolically healthy normal weight individuals. Among overweight indi-
viduals, metabolically healthy individuals had a lower colorectal cancer risk than metaboli-
cally unhealthy individuals. Finally, similar associations were seen when the researchers
used waist circumference instead of BMI as the measure of adiposity.
What Do These Findings Mean?
These findings suggest that normal weight individuals with hyperinsulinemia (the meta-
bolically unhealthy normal weight phenotype) have a higher risk of colorectal cancer than
normal weight individuals without hyperinsulinemia. They also suggest that metabolically
unhealthy overweight individuals have a higher risk of colorectal cancer than metabolically
healthy overweight individuals. The accuracy of these findings may be limited by the
method the researchers used to classify individuals as hyperinsulinemic—there is no uni-
versally accepted clinical definition for using C-peptide level to diagnose hyperinsuline-
mia. Nevertheless, these findings suggest that the assessment of insulin levels in
conjunction with adiposity measures might be a better way to assess an individual’s colo-
rectal cancer risk than simply measuring adiposity, and might help to identify those indi-
viduals at high risk of colorectal cancer who are most likely to benefit from targeted
interventions designed to prevent the onset of clinical disease.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001988.
• The US National Cancer Institute provides information for patients about all aspects of
colorectal cancer; it also provides more detailed information colorectal cancer for health
professionals and information on cancer risk and obesity
• The UK National Health Service Choices website has information and personal stories
about colorectal cancer and information on obesity
• The not-for-profit organization Cancer Research UK provides information about
colorectal cancer and about the association between cancer and obesity
• MedlinePlus provides links to further resources about colorectal cancer and about
obesity
• Wikipedia has a page on hyperinsulinemia (note that Wikipedia is a free online encyclo-
pedia that anyone can edit; available in several languages)
• More information about the EPIC study is available
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